{"Clinical Trial ID": "NCT02635737", "Intervention": ["INTERVENTION 1:", "\u2022 Placement of the Sentimark device", "Sentimark device placed in women with mastectomy surgery", "Sentimark: Placement of a metal clip with paramagnetic properties for the location of tumours"], "Eligibility": ["Incorporation criteria:", "The participant is willing and able to give his or her informed consent to participate in the study;", "Women 18 years of age or older;", "- Diagnosis of breast cancer (invasive or dicis);", "To enable his general practitioner and consultant, if necessary, to be informed of his participation in the study;", "In the course of mammary mastectomy surgery.", "- Exclusion criteria:", "\u2022 Patients with a Pacemaker or implanted device;", "\u2022 Patients requiring MRI prior to surgery;", "\u2022 Patients with known coagulopathy or receiving anticoagulant medicinal products, including warfarin, heparin, clopidogrel or rivaroxaban;", "Patients receiving neoadjuvant chemotherapy;", "Pregnant or lactating patients;", "Patients to be immediately reconstituted in the breast;", "Patients who have received an injection of Sienna (iron oxide) in the previous six months;", "Patients with an existing breast haematoma near the target lesion."], "Results": ["Performance measures:", "Migration of the Sentimark device", "- Displacement of device >10mm between mammograms, clip position >40mm from target lesion", "Time limit: 1 to 4 weeks after placement", "Results 1:", "Title of the arm/group: Placement of the Sentimark device", "Description of the arm/group: Sentimark device placed in women with mastectomy surgery", "Sentimark: Placement of a metal clip with paramagnetic properties for the location of tumours", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measure: percentage of eagle seed migration >10mm 100"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/29 (0.00 per cent)"]}